Scholars@Duke

ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits growth of multiple primary central nervous system tumor types.

Publication ,  Conference
Rich, JN; Loncar, D; Keir, S; Wheeler, C; Dimery, I; Bigner, DD; Friedman, HS
Published in: CLINICAL CANCER RESEARCH
December 1, 2003
Link to item

Duke Scholars

Darell Doty Bigner
Author Darell Doty Bigner Neurosurgery
Henry Seth Friedman
Author Henry Seth Friedman Neurosurgery, Neuro-Oncology

Published In

CLINICAL CANCER RESEARCH

ISSN

1078-0432

Publication Date

December 1, 2003

Volume

9

Issue

16

Start / End Page

6143S / 6143S

Location

BOSTON, MASSACHUSETTS

Publisher

AMER ASSOC CANCER RESEARCH

Conference Name

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rich, J. N., Loncar, D., Keir, S., Wheeler, C., Dimery, I., Bigner, D. D., & Friedman, H. S. (2003). ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits growth of multiple primary central nervous system tumor types. In CLINICAL CANCER RESEARCH (Vol. 9, pp. 6143S-6143S). BOSTON, MASSACHUSETTS: AMER ASSOC CANCER RESEARCH.
Rich, J. N., D. Loncar, S. Keir, C. Wheeler, I. Dimery, D. D. Bigner, and H. S. Friedman. “ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits growth of multiple primary central nervous system tumor types.” In CLINICAL CANCER RESEARCH, 9:6143S-6143S. AMER ASSOC CANCER RESEARCH, 2003.
Rich JN, Loncar D, Keir S, Wheeler C, Dimery I, Bigner DD, et al. ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits growth of multiple primary central nervous system tumor types. In: CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2003. p. 6143S-6143S.
Rich, J. N., et al. “ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits growth of multiple primary central nervous system tumor types.” CLINICAL CANCER RESEARCH, vol. 9, no. 16, AMER ASSOC CANCER RESEARCH, 2003, pp. 6143S-6143S.
Rich JN, Loncar D, Keir S, Wheeler C, Dimery I, Bigner DD, Friedman HS. ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits growth of multiple primary central nervous system tumor types. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2003. p. 6143S-6143S.

Published In

CLINICAL CANCER RESEARCH

ISSN

1078-0432

Publication Date

December 1, 2003

Volume

9

Issue

16

Start / End Page

6143S / 6143S

Location

BOSTON, MASSACHUSETTS

Publisher

AMER ASSOC CANCER RESEARCH

Conference Name

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis